Perspektiven der Botulinumtoxintherapie der Dystonien

Zusammenfassung

Die therapeutische Anwendung von Botulinumtoxin (BT) hat sich seit ihrer Einführung in die deutsche Neurologie vor zwölf Jahren als erfolgreichstes Verfahren zur Behandlung von Dystonien und anderen Muskelüberaktivitätssyndromen etabliert. In der vorliegenden Übersicht werden immunologische Aspekte der BT-Therapie, Konversionsfaktoren zum Vergleich verschiedener BT-Päparationen, Anwendungsmöglichkeiten der Elektromyographie bei der Planung und Durchführung der BT-Therapie, Entwicklungen neuer BT-Präparationen und Versorgungsstrukturen der BT-Therapie dargestellt.

Abstract

Therapeutic use of botulinum toxin (BT) is now established as the most effective treatment for dystonia and other muscle hyperactivity syndromes after it was introduced to German neurology 12 years ago. In this review, immunological aspects of BT therapy, conversion factors for comparison of different BT preparations, use of electromyography for planning and application of BT therapy, development of new BT preparations and health care system structures for providing BT therapy are presented.

Key words

Botulinum toxin - Therapy - Dystonia - Immunology - Conversion factors - Electromyography - Type A - Type B - Health care system

Literatur

• 1 Dressler D, Benecke R, Conrad B. Botulinum-Toxin in der Therapie kraniozervikaler Dystonien.  Nervenarzt. 1989;  60 386-393
• 2 Dressler D. Botulinum-Toxin-Therapie. Stuttgart; Thieme Verlag 1995
• 3 Dressler D. Botulinum Toxin Therapy. Stuttgart, New York; Thieme Verlag 2000
• 4 Jankovic J, Hallett M. Therapy with Botulinum Toxin. New York, Basel, Hongkong; Marcel Dekker 1994
• 5 Moore P. Handbook of Botulinum Toxin Treatment. Oxford; Blackwell Science 1995
• 6 Laskawi R, Roggenkämper P. Botulinum-Toxin-Therapie im Kopf-Hals-Bereich. München; Urban & Vogel 1999
• 7 Biglan A W, Gonnering R, Lockhart L B, Rabin B, Fuerste F H. Absence of antibody production in patients treated with botulinum A toxin.  Am J Ophthalmol. 1986;  101 232-235
• 8 Gonnering R S. Negative antibody response to long-term treatment of facial spasm with botulinum toxin.  Am J Ophthalmol. 1988;  105 313-315
• 9 Wittstock M, Benecke R, Bigalke H, Dressler D. Quantitative antibody status of patients with continued sensitivity to long-term botulinum toxin therapy.  Neurology. 2001;  56 (Suppl 3) A347
• 10 Kessler K R, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group.  J Neurol. 1999;  246 265-274
• 11 Herrmann J, Mall V, Bigalke H, Geth K, Korinthenberg R, Heinen F. Secondary non-response due to development of neutralising antibodies to botulinum toxin A during treatment of children with cerebral palsy.  Neuropediatrics. 2000;  31 333-334
• 12 Pearce L B, Borodic G E, First E R, MacCallum R D. Measurement of botulinum toxin activity: evaluation of the lethality assay.  Toxicol Appl Pharmacol. 1994;  128 69-77
• 13 Göschel H, Wohlfahrt K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin: Neutralizing and nonneutralizing antibodies - therapeutic consequences.  Exp Neurol. 1997;  147 96-102
• 14 Palace J, Nairne A, Hyman N, Doherty T V, Vincent A. A radioimmuno-precipitation assay for antibodies to botulinum A.  Neurology. 1998;  50 1463-1466
• 15 Dressler D, Dirnberger G, Bhatia K, Quinn N P, Irmer A, Bigalke H, Marsden C D. Botulinum toxin antibody testing: comparison between the mouse diaphragm bioassay and the mouse lethality bioassay.  Mov Disord. 2000;  15 973-976
• 16 Dressler D, Rothwell J C, Bigalke H. The sternocleidomastoid test: an in-vivo assay to investigate botulinum toxin antibody formation in man.  J Neurol. 2000;  247 630-632
• 17 Kessler K R, Benecke R. The EBD test - a clinical test for the detection of antibodies to botulinum toxin type A.  Mov Disord. 1997;  12 95-99
• 18 Dressler D. Botulinum toxin therapy failure: causes, evaluation procedures and management strategies.  Eur J Neurol. 1997;  4 (suppl 2) S67-S70
• 19 Dressler D. Clinical features of secondary failure of botulinum toxin therapy. Eur Neurol 2001 (in press)
• 20 Dressler D. Managing Patients with Botulinum Toxin Antibodies. In: Brin MF, Jankovic J, Hallett M (eds) Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia; Lippincott Williams & Wilkins 2001 (in press)
• 21 Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis.  Mov Disord. 1994;  9 213-217
• 22 Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections.  Neurology. 1995;  45 1743-1746
• 23 Dressler D, Dirnberger G. Risk factors for therapy failure.  Mov Disord. 2000;  15 (suppl 2) 51
• 24 Dressler D. Complete secondary botulinum toxin therapy failure in blepharospasm.  J Neurol. 2000;  247 809-810
• 25 Poewe W, Wissel J. Experience with botulinum toxin in cervical dystonia. In: Jankovic J, Hallett M (eds) Therapy with Botulinum Toxin. New York, Basel, Hongkong; Marcel Dekker 1994: 267-278
• 26 First E R, Pearce L B, Borodic G E. Dose standardisation of botulinum toxin.  Lancet. 1994;  343 1035
• 27 van den Bergh P, Lison D. Dose standardisation of BTX. 3rd International Dystonia Symposium, October 9 - 11, 1996,. Miami, Florida; Chicago, Illinois; Affiliated National Dystonia Associations 1996: p30
• 28 Hambleton P, Pickett A M. Potency equivalence of botulinum toxin preparations.  J Roy Soc Med. 1994;  87 719
• 29 Dressler D, Rothwell J C. Electromyographic quantification of the paralysing effect of botulinum toxin.  Eur Neurol. 2000;  43 13-16
• 30 Sloop R R, Escutin R O, Matus J A, Cole B A, Peterson G W. Dose-response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A.  Neurology. 1996;  46 1382-1386
• 31 Sloop R R, Cole B A, Escutin R O. Human response to botulinum toxin injection: type B compared with type A.  Neurology. 1997;  49 189-194
• 32 Wohlfahrt K, Göschel H, Frevert J, Dengler R, Bigalke H. Botulinum A toxins: units versus units.  Naunyn Schmiedeberg's Arch Pharmacol. 1997;  355 335-340
• 33 Dressler D, Rothwell J C, Marsden C D. Comparing biological potencies of Botox® and Dysport® with a mouse diaphragm model may mislead.  J Neurol. 1998;  245 332
• 34 Ostergaard L, Fuglsang-Frederiksen A, Sjo O, Werdelin L, Winkel H. Quantitative EMG in cervical dystonia.  Electromyogr Clin Neurophysiol. 1996;  36 179-185
• 35 Van Gerpen J A, Matsumoto J Y, Ahlskog J E, Maraganore D M, McManis P G. Utility of an EMG mapping study in treating cervical dystonia.  Muscle Nerve. 2000;  23 1752-1756
• 36 Dressler D. Electromyographic evaluation of cervical dystonia for planning of botulinum toxin therapy.  Eur J Neurol. 2000;  7 713-718
• 37 Comella C L, Buchman A S, Tanner C M, Brown-Toms N C, Goetz C G. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance.  Neurology. 1992;  42 878-882
• 38 Blitzer A, Brin M F, Stewart C F. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.  Laryngoscope. 1998;  108 1435-1441
• 39 Geenen C, Consky E, Ashby P. Localizing muscles for botulinum toxin treatment of focal hand dystonia.  Can J Neurol Sci. 1996;  23 194-197
• 40 Brashear A, Lew M F, Dykstra D D, Comella C L, Factor S A, Rodnitzky R L, Trosch R, Singer C, Brin M F, Murray J J, Wallace J D, Willmer-Hulme A, Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.  Neurology. 1999;  53 1439-1446
• 41 Brin M F, Lew M F, Adler C H, Comella C L, Factor S A, Jankovic J, O'Brien C, Murray J J, Wallace J D, Willmer-Hulme A, Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.  Neurology. 1999;  53 1431-1438
• 42 Dressler D, Benecke B. Autonomic side effects of botulinum toxin type B therapy. Mov Disord 2001 (in press)